Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

319 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy of cannabidiol in convulsive and nonconvulsive seizure types associated with treatment-resistant epilepsies in the Expanded Access Program.
Flamini RJ, Comi AM, Bebin EM, Chez MG, Clark G, Devinsky O, Hussain SA, Lyons PD, Patel AD, Rosengard JL, Sahebkar F, Segal E, Seltzer L, Szaflarski JP, Weinstock A. Flamini RJ, et al. Among authors: szaflarski jp. Epilepsia. 2023 Aug;64(8):e156-e163. doi: 10.1111/epi.17665. Epub 2023 Jun 15. Epilepsia. 2023. PMID: 37243404
Cannabinoids and epilepsy - Introduction.
Szaflarski JP, Devinsky O. Szaflarski JP, et al. Epilepsy Behav. 2017 May;70(Pt B):277. doi: 10.1016/j.yebeh.2017.01.015. Epub 2017 Feb 16. Epilepsy Behav. 2017. PMID: 28215997 No abstract available.
Affiliate stigma and caregiver burden in intractable epilepsy.
Hansen B, Szaflarski M, Bebin EM, Szaflarski JP. Hansen B, et al. Among authors: szaflarski m, szaflarski jp. Epilepsy Behav. 2018 Aug;85:1-6. doi: 10.1016/j.yebeh.2018.05.028. Epub 2018 Jun 7. Epilepsy Behav. 2018. PMID: 29886019
Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies: Expanded access program results.
Szaflarski JP, Bebin EM, Comi AM, Patel AD, Joshi C, Checketts D, Beal JC, Laux LC, De Boer LM, Wong MH, Lopez M, Devinsky O, Lyons PD, Zentil PP, Wechsler R; CBD EAP study group. Szaflarski JP, et al. Epilepsia. 2018 Aug;59(8):1540-1548. doi: 10.1111/epi.14477. Epub 2018 Jul 12. Epilepsia. 2018. PMID: 29998598 Free PMC article.
Open-label use of highly purified CBD (Epidiolex®) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes.
Devinsky O, Verducci C, Thiele EA, Laux LC, Patel AD, Filloux F, Szaflarski JP, Wilfong A, Clark GD, Park YD, Seltzer LE, Bebin EM, Flamini R, Wechsler RT, Friedman D. Devinsky O, et al. Among authors: szaflarski jp. Epilepsy Behav. 2018 Sep;86:131-137. doi: 10.1016/j.yebeh.2018.05.013. Epub 2018 Jul 11. Epilepsy Behav. 2018. PMID: 30006259 Free article.
Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study.
Szaflarski JP, Bebin EM, Cutter G, DeWolfe J, Dure LS, Gaston TE, Kankirawatana P, Liu Y, Singh R, Standaert DG, Thomas AE, Ver Hoef LW; UAB CBD Program. Szaflarski JP, et al. Epilepsy Behav. 2018 Oct;87:131-136. doi: 10.1016/j.yebeh.2018.07.020. Epub 2018 Aug 9. Epilepsy Behav. 2018. PMID: 30100226 Free article. Clinical Trial.
319 results